SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Derivatives -- Ignore unavailable to you. Want to Upgrade?


To: LLCF who wrote (213)5/17/1999 11:19:00 PM
From: Jim Oravetz  Read Replies (1) | Respond to of 555
 
Recently, Genentech has been in the news over the sale of growth hormone and whether they own the patents. BTGC was sued by Genentech over sales of its growth hormone, Bio-Tropin.

From the BTGC profile:
The Company's marketed products include Bio-Tropin(TM) (human growth hormone), which is currently being marketed in several countries in Europe, Latin America, Asia and the Far East for the treatment of growth hormone deficiency in children;

As a result, they are(were) waiting until the patents expire before starting sales in the US.

This post details some of the BTGC/Genentech verbage regarding what was not proved by BTGC in defence of its product in court..and speculates the impact on BTGC stock. Any comments? Thanks.
Message 9573192

Note: I own some BTGC.
Jim